Neurogranin as cerebrospinal fluid biomarker for Alzheimer disease
| Autor: | Kaj Blennow, Anne M. Fagan, Ulf Andreasson, Sebastiaan Engelborghs, Charlotte E. Teunissen, Elizabeth M. Herries, Henrik Zetterberg, Wiesje M. van der Flier, Ann De Vos, Philip Scheltens, Eugeen Vanmechelen, Maria Bjerke, Dan L. Crimmins, Eline A.J. Willemse, Jack H. Ladenson |
|---|---|
| Přispěvatelé: | Amsterdam Neuroscience - Neurodegeneration, Clinical chemistry, APH - Personalized Medicine, APH - Methodology, Neurology, Educational Science, Clinical sciences |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Clinical Biochemistry CSF Enzyme-Linked Immunosorbent Assay Context (language use) Antibodies Cohort Studies Epitopes 03 medical and health sciences 0302 clinical medicine Alzheimer Disease Internal medicine medicine Humans Dementia Neurogranin Cognitive decline Vascular dementia Biology Cerebrospinal Fluid Medicine(all) Dementia with Lewy bodies business.industry Biochemistry (medical) medicine.disease 030104 developmental biology Endocrinology biomarker Biomarker (medicine) Electrophoresis Polyacrylamide Gel Human medicine Alzheimer's disease business Biomarkers 030217 neurology & neurosurgery dementia |
| Zdroj: | Clinical chemistry : international journal of laboratory medicine and molecular diagnostics Willemse, E A J, De Vos, A, Herries, E M, Andreasson, U, Engelborghs, S, Van Der Flier, W M, Scheltens, P, Crimmins, D, Ladenson, J H, Vanmechelen, E, Zetterberg, H, Fagan, A M, Blennow, K, Bjerke, M & Teunissen, C E 2018, ' Neurogranin as cerebrospinal fluid biomarker for Alzheimer disease : An assay comparison study ', Clinical Chemistry, vol. 64, no. 6, pp. 927-937 . https://doi.org/10.1373/clinchem.2017.283028 Clinical Chemistry, 64(6), 927-937. Oxford University Press |
| ISSN: | 0009-9147 |
| DOI: | 10.1373/clinchem.2017.283028 |
| Popis: | BACKGROUND Neurogranin in cerebrospinal fluid (CSF) correlates with cognitive decline and is a potential novel biomarker for Alzheimer disease (AD) dementia. We investigated the analytical and diagnostic performance of 3 commonly used neurogranin assays in the same cohort of patients to improve the interpretability of CSF neurogranin test results. METHODS The neurogranin Erenna® assay from Washington University, St. Louis, MO (WashU); ELISA from ADx Neurosciences; and ELISA from Gothenburg University, Mölndal, Sweden (UGot), were compared using silver staining and Western blot after gel electrophoresis. Clinical performance of the 3 assays was compared in samples from individuals diagnosed with subjective cognitive decline (n = 22), and in patients with AD (n = 22), frontotemporal dementia (n = 22), dementia with Lewy bodies (n = 22), or vascular dementia (n = 20), adjusted for sex and age. RESULTS The assays detected different epitopes of neurogranin: the WashU assay detected the N-terminal part of neurogranin (S10-D23) and a C-terminal part (G49-G60), the ADx assay detected C-terminal neurogranin truncated at P75, and the UGot assay detected the C-terminal neurogranin with intact ending (D78). Spearman ρ was 0.95 between ADx and WashU, 0.87 between UGot and WashU, and 0.81 between UGot and ADx. ANCOVA (analysis of covariance) showed group differences for ranked neurogranin concentrations in each assay (all P < 0.05), with specific increases in AD. CONCLUSIONS Although the 3 assays target different epitopes on neurogranin and have different calibrators, the high correlations and the similar group differences suggest that the different forms of neurogranin in CSF carry similar diagnostic information, at least in the context of neurodegenerative diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|